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Purpose: To evaluate 3-year safety and intraocular pressure (IOP) following two trabecular 
microbypass stents in phakic and pseudophakic subjects with open-angle glaucoma (OAG) not 
controlled on preoperative medication.
Patients and methods: In this prospective pilot study, phakic or pseudophakic subjects with 
OAG and IOP between 18 mmHg and 30 mmHg on one preoperative topical ocular hypotensive 
medication underwent medication washout. Thirty-nine qualified subjects with preoperative 
unmedicated IOP $22 mmHg and #38 mmHg received two stents. Postoperative examinations 
were scheduled at Day 1, Week 1, Months 1, 3, 6, and 12, and semiannually through Month 60. 
Ocular hypotensive medication was considered if postoperative IOP exceeded 21 mmHg. IOP, 
medication use, and safety were assessed at each visit. Subject follow-up through Month 36 
was completed.
Results: Thirty-six eyes (92.3%; 95% confidence interval [CI] 79.1%, 98.4%) achieved the 
primary efficacy end point of Month 12 reduction in IOP $20% from baseline (unmedicated 
IOP) without ocular hypotensive medication. Four subjects required medication during the 
Month 36 follow-up period. Mean IOP at 36 months for subjects not taking medication 
was 15.2 mmHg. At 36 months, subjects sustained mean IOP decrease of 9.1±2.7 mmHg 
(95% CI 8.0 mmHg, 10.14 mmHg), or 37% IOP reduction, from unmedicated baseline 
IOP. Compared to preoperative medicated IOP, subjects had mean reduction at Month 36 
of 5.5±2.7 mmHg (95% CI 4.5 mmHg, 6.6 mmHg), or 26% reduction. Both measures of 
IOP reduction were highly significant (P,0.001). Other than one case of early postopera-
tive hyphema that resolved at 1 week, no postoperative adverse events were attributed to 
stent implantation.
Conclusion: In a pilot study, two trabecular microbypass stents to treat OAG subjects on one 
preoperative medication provided statistically significant, sustained, and safe reduction of IOP 
to #15 mmHg without medication through 36 months.
Keywords: iStent, MIGS, OAG, intraocular pressure, IOP reduction
Introduction
Microinvasive glaucoma surgery (MIGS) using ab interno trabecular microbypass 
stents has been shown to be safe and effective for mild-to-moderate glaucoma subjects 
in conjunction with cataract surgery. These stents bypass the trabecular meshwork, 
which is thought to be the primary source of resistance to aqueous drainage in most 
open-angle glaucomas (OAGs), in order to improve outflow through the natural 
physiologic pathway and reduce intraocular pressure (IOP). The iStent® Trabecular 
Micro-Bypass (Glaukos Corp., Laguna Hills, CA, USA) is the first of its kind in the 
evolving category of MIGS devices and has been shown to offer a safe and effective 
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way to lower IOP and medication use in patients with mild-
to-moderate  glaucoma. One small, single-centered prospec-
tive, randomized controlled trial1,2 and a large, multicentered 
prospective, randomized study3,4 have shown the safety and 
effectiveness of iStent in conjunction with cataract sur-
gery to reduce IOP and medication burden compared with 
cataract surgery alone for up to 5 years postoperative; and 
other studies have corroborated the effects of safe reduction 
in IOP and medication use vs preoperative parameters for 
12 months and 54 months, respectively.5,6
Use of multiple stents to further increase the outflow 
has been shown to be viable, both in a theoretical in 
vitro perfusion model and in clinical experience. Bahler 
et al’s predictive model work showed an increase in the 
facility of outflow after implantation of multiple stents.7 
Belovay et al found that implantation of multiple stents 
during cataract surgery provided mean reduction in IOP 
to ,15 mmHg with reduction in medications through 
1 year postoperative.8
Although prior work has established the favorable long-
term benefit/risk profile of iStent used in conjunction with 
cataract surgery, the long-term efficacy of trabecular bypass 
stent implantation as a sole procedure to manage OAG 
without the potential pressure lowering effect of cataract 
surgery has not been established. It is difficult to assess the 
sole effect of iStent on IOP reduction when implanted dur-
ing cataract surgery. However, this information is critical 
for weighing the benefit of surgical therapy in earlier stages 
of the disease state. Up until the advent of MIGS, trab-
eculectomy has been recognized as the standard surgical 
treatment for patients with glaucoma, as have its associated 
significant complications including hypotony, bleb leaks, 
cataract progression, choroidal effusion/hemorrhage, and 
resultant visual deterioration.9 Earlier surgical intervention 
in glaucoma with a safe procedure that restores natural physi-
ologic outflow to achieve target IOP could advance clinical 
care and significantly reducing drug burden could improve 
the patient’s quality of life. Thus, a series of prospective 
studies were designed to examine outcomes following stent 
implantation without cataract surgery in patients at various 
stages of OAG disease.
This current pilot study, one of the first in a series of 
studies by the MIGS Study Group, describes outcomes 
through 3 years postoperatively after two iStent devices were 
implanted as a stand-alone procedure without concomitant 
cataract surgery in subjects with OAG not controlled with a 
single preoperative topical ocular hypotensive medication. 
This is the first published report of outcomes in our study 
designed for follow-up through 5 years postoperative.
Materials and methods
subjects
This prospective, open-label study involved phakic or 
pseudophakic subjects with OAG (including primary, pig-
mentary, and pseudoexfoliative). Subjects were required 
to have a medicated IOP of $18 mmHg and #30 mmHg 
at screening on one topical ocular hypotensive medication. 
After washout of ocular hypotensive medication (4 weeks 
for beta-blockers and prostaglandin analogs, 2 weeks for 
alpha agonists, 5 days for carbonic anhydrase inhibitors), 
IOP was required to be $22 mmHg and #38 mmHg at 
baseline for inclusion in the trial. Other inclusion cri-
teria included preoperative best-corrected visual acuity 
(BCVA) of 20/100 or better, visual field defects or nerve 
abnormality characteristic of glaucoma, willingness to 
attend follow-up visits for 5 years postoperatively, and 
informed consent.
The subjects with the following conditions were 
excluded: narrow angle or secondary glaucoma,  aphakia 
or pseudophakia with anterior chamber intraocular lenses, 
prior stent implantation, peripheral anterior synechiae, 
prior argon laser trabeculoplasty, prior iridectomy or 
laser iridotomy, active corneal inflammation or edema, 
prior corneal surgery, corneal opacities/disorders inhibit-
ing visualization of the nasal angle, elevated episcleral 
venous pressure, functionally significant visual field loss, 
and chronic or active ocular inflammation.
study group and protocol registration
The MIGS Study Group was formed in order to evaluate 
iStent technology as titratable therapy in a series of pro-
spective studies in over 2,000 patients. For many of the 
surgeons, this was their first experience implanting a MIGS 
device. The study group comprises visiting surgeons and 
one staff surgeon at one investigational site (S.V. Malayan 
Ophthalmology Centre, Yerevan, Armenia).
The study protocol received Ethics Committee approval, 
and informed consent was obtained from patients for study 
participation. Methods of data collection were in accordance 
with the Declaration of Helsinki (2008). The study was 
registered and assigned clinical trial registration number 
NCT1252862 (Clinicaltrials.gov).
istent, surgical technique, examinations, 
and follow-up
The iStent is a heparin-coated, gamma-sterilized device 
made from titanium. The one-piece device is ~1.0 mm 
in length, ~0.33 mm in height, with a snorkel bore diam-
eter of 120 µm. Left-flow stents and right-flow stents are 
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available. These stents are identical except that the “foot” 
of each faces opposite directions to facilitate nasal stent 
placement and to optimize distal flow through collector 
channels. When implanted, the snorkel is located in the 
anterior chamber, and the open half-pipe lumen (foot) is 
located in the canal of Schlemm. A stainless steel single-
use inserter containing the preloaded stent is used for stent 
implantation.
Using the technique described by Samuelson et al and 
Spiegel et al,1,10 two iStent devices were implanted through 
the trabecular meshwork into Schlemm’s canal at the nasal 
position, separated by two clock hours and facing opposite 
directions (Figure 1). Viscoelastic was removed via manual 
irrigation with balanced salt solution. A postoperative regi-
men of topical anti-inflammatory and anti-infective medica-
tions was followed for 4 weeks. Topical ocular hypotensive 
medication was considered for subjects in whom IOP 
increased to .21 mmHg.
Following the informed consent process, the screening 
examination included slit-lamp biomicroscopy, indirect 
ophthalmoscopy, measurement of IOP, BCVA (via Early 
Treatment of Diabetic Retinopathy Study system), visual field 
(automated threshold visual field via Humphrey 24-2, Swedish 
Interactive Thresholding Algorithm (SITA) Standard), and 
pachymetry. After washout of ocular hypotensive medications 
according to the medication class, subjects underwent baseline 
examination for evaluation of IOP. Those subjects whose IOP 
values were within the required range were then scheduled to 
undergo surgery. Follow-up visits were scheduled at Day 1, 
Week 1, Months 1, 3, 6, and 12, followed by visits every 
6 months for a total of 5 years and consisted of examination 
parameters similar to the set of preoperative measurements. 
Glaucoma-trained ophthalmologists at the eye hospital per-
formed preoperative and postoperative IOP measurements at 
9 am ±1 hour. In addition, the medical monitor of the trial (LJK) 
evaluated the IOP of a sample of these patients as well.
study end points and statistical analysis
Two efficacy end points were defined in the study protocol. 
Month 12 IOP reduction $20% without medication vs 
baseline unmedicated IOP comprised the primary end point, 
and Month 12 IOP #18 mmHg without medication was the 
secondary end point. Subjects were considered responders 
if they met all criteria for the end points, including no use 
of ocular hypotensive medications at the Month 12 exami-
nation and no secondary surgical intervention to reposition 
or remove stents or other procedure that could affect IOP 
before the Month 12 examination. We assessed additional 
efficacy at Month 36, including mean unmedicated IOP, mean 
change in IOP from preoperative to Month 36 unmedicated 
IOP, and medication use. Safety analyses through Month 36 
involved assessment of adverse events, BCVA, slit lamp 
findings, and pachymetry.
The per protocol analysis population included qualified 
subjects who underwent implantation of two stents. Exact 
95% confidence intervals (CIs) based on a binomial distri-
bution were calculated for responder rates of proportional 
analyses. For continuous variables, such as mean IOP, 95% 
CIs were calculated using the t-distribution. Change in IOP 
from preoperative to Month 36 was assessed via paired t-tests. 
Statistical analysis software was used (PC-SAS software, 
Version 9.3; SAS Institute Inc., Cary, NC, USA).
Results
subject disposition and demographics
A total of 94 subjects were screened for study participa-
tion. Eighteen subjects did not meet screening criteria, and 
36 subjects did not meet baseline criteria (eg, did not 
$
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Figure 1 example of istent locations.
Notes: (A) OD (right eye): left stent at 2 o’clock, right stent at 4 o’clock. (B) Os (left eye): left stent at 8 o’clock, right stent at 10 o’clock.
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 complete medication washout, withdrew consent, IOP too 
high after medication washout). The remaining 40 quali-
fied subjects underwent surgery. In addition, two subjects 
who were taking combination medications preoperatively 
underwent surgery. Because their preoperative medication 
burden was later categorized as two medications, these 
two subjects were classified as protocol deviations. All 42 
surgeries were performed at a single investigational site 
(S.V. Malayan Ophthalmology Centre, Yerevan, Armenia), 
and surgeries were performed by six surgeons, including 
the local surgeon and five visiting surgeons from the USA 
and Canada.
Of the 42 subjects who underwent surgery, 39 subjects 
were included in the per protocol analysis population 
( Figure 2). Of the three subjects excluded from the per pro-
tocol population, two subjects with preoperative combination 
medications did not meet the screening criteria (discussed 
earlier) and one subject underwent implantation of only one 
stent due to unintended subject movement during surgery. 
The per protocol analysis population also includes data 
from five subjects who presented with preoperative BCVA 
of 20/200 (worse than the inclusion criteria of 20/100 or 
better), four of whom had eccentric vision, who were granted 
 protocol waivers by the sponsor and allowed to participate 
in the study. All 39 per protocol subjects presented with 
follow-up through 24 months. Nine subjects were exited 
after the Month 24 examination and before the Month 36 
examination. Two subjects had died, two subjects had moved 
out of the country, and five subjects were lost to follow-up.
Demographics are shown in Table 1. The mean age 
at enrollment was 66.7±10.0 years. Twenty-two subjects 
(56.4%) were male. Subjects were primarily phakic (89.7%) 
with brown irides (94.9%). The mean visual field (mean 
deviation) was -4.95±2.52 dB. The mean cup:disk (C:D) 
ratio was 0.7±0.2, and eleven eyes (28.2%) had C:D ratios 
of worse than 0.8. Subjects presented with mean pachymetry 
values of 535±32.7 µm. Mean medicated IOP at screening 
was 20.6±2.0 mmHg, with most subjects (56.4%) taking 
beta-blockers preoperatively. Mean IOP following medica-
tion washout was 24.1±1.4 mmHg.
intraocular pressure
The primary efficacy end point (IOP reduction $20% 
from baseline to 12 months without medication) and the 
6FUHHQLQJH[DPLQDWLRQQ  'LGQRWPHHWVFUHHQLQJFULWHULDQ 
'LGQRWPHHWEDVHOLQHFULWHULDQ 
&RPSOLFDWLRQVRIVXUJHU\Q 
8QGHUZHQWVXUJHU\Q 
8QGHUZHQWVXUJHU\Q 
3HUSURWRFROSRSXODWLRQQ 
%DVHOLQHH[DPLQDWLRQQ 
)ROORZXSWKURXJK0Q 
)ROORZXSWKURXJK0Q 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Figure 2 Subject flowchart.
Abbreviations: lTF, lost to follow up; M, month.
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Table 1 Demographic and preoperative characteristics
Variable Statistic
n 39
Mean age (years)
Mean ± sD 66.7±10.0
range 50–90
sex
Male 22 (56.4%)
Female 17 (43.6%)
race/ethnicity
White 39 (100.0%)
lens status
Phakic 35 (89.7%)
Pseudophakic 4 (10.3%)
eye
OD 16 (41.0%)
Os 23 (59.0%)
iris color
Brown 37 (94.9%)
Blue 2 (5.1%)
Mean medicated iOP (mmhg)
Mean ± sD 20.6±2.0
Medications
Beta-blocker 22 (56.4%)
Carbonic anhydrase inhibitor 10 (25.6%)
Prostaglandin analog 6 (15.4%)
alpha agonist 1 (2.6%)
Visual field (dB)
Mean deviation, mean ± sD -4.95±2.52
Pattern standard deviation, mean ± sD 3.05±2.15
C:D ratio
Mean ± sD 0.7±0.2
range 0.4–0.95
Mean pachymetry (µm)
Mean ± sD 535±32.7
Mean postwashout iOP (mmhg)
Mean ± sD 24.1±1.4
Note: C:D ratio denotes cup:disk ratio.
Abbreviations: sD, standard deviation; iOP, intraocular pressure; OD, right eye; 
Os, left eye.
secondary end point (IOP #18 mmHg at 12 months without 
 medication) were each achieved by 92.3% of subjects (n=36; 
95% CI 79.1%, 98.4%; Figure 3). The mean reduction in 
IOP from baseline was 44%. Only the three subjects taking 
ocular hypotensive medications at 12 months were consid-
ered nonresponders for each of the efficacy end points. No 
 subject underwent secondary surgical intervention prior to the 
Month 12 examination that could affect IOP. Most subjects 
maintained these target IOP thresholds through Month 36, 
with IOP reduction $20% achieved by 86.2% (n=25; 95% 
CI 68.3%, 96.1%) and IOP #18 mmHg achieved by 89.7% 
(n=26; 95% CI 72.6%, 97.8%).
Mean IOP for subjects not using ocular  hypotensive med-
ication was 13.5±1.8 mmHg at Month 12 (95% CI 12.9 
mmHg, 14.1 mmHg), 13.5±2.1 mmHg at Month 24 (95% 




 0RQWKQ 
R
IH\
HV
0RQWKQ 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Figure 3 Proportional analyses of iOP outcomes at annual examinations through 
Month 36, per protocol population.
Notes: iOP values were excluded after secondary surgeries. One subject had 
cataract surgery after M24 and was excluded from the M36 analyses.
Abbreviations: iOP, intraocular pressure; w/o, without; med, medication; M, month.
CI 12.8 mmHg, 14.2 mmHg), and 15.2±2.1 mmHg (95% 
CI 14.3 mmHg, 16.0 mmHg) at Month 36. In the consistent 
cohort of subjects followed through Month 36 and not using 
medications, mean IOP values were similar to the set of 
all eyes. Mean Month 36 IOP decrease from unmedicated 
baseline IOP was 9.1±2.7 mmHg (95% CI 8.0 mmHg, 
10.14 mmHg). Compared to preoperative medicated 
IOP, these subjects experienced a mean IOP reduction of 
5.5±2.7 mmHg (95% CI 4.5 mmHg, 6.6 mmHg) at their 
Month 36 examination. Both the mean reduction in Month 36 
IOP from unmedicated baseline and the mean Month 36 IOP 
decrease from subjects’ medicated screening IOP were highly 
significant (P,0.001 in each case). Figure 4 shows boxplots 
of IOP over time for the consistent cohort.
Ocular hypotensive medications
The vast majority of eyes (35/39 or 89.7%) did not require 
ocular hypotensive medications following two stent implan-
tations. Of the four subjects treated with postoperative medi-
cation, medication was initiated at 1 week postoperative in 




6&5
,23
PP
+J
%/ 0 0 0 0 0 0 0
Figure 4 iOP over time, consistent cohort through Month 36 (n=30).
Notes: iOP values were excluded for eyes on postoperative medication and after 
secondary surgeries. One subject had cataract surgery after M24 and was excluded 
from subsequent statistics.
Abbreviations: iOP, intraocular pressure; M, month; sCr, screening; Bl, baseline.
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two subjects and at 1 month postoperative in two subjects. 
Medication use was discontinued in one subject at the 
Month 3 examination and in one subject at the Month 24 
examination. Thus, three subjects were on medication at 
the Month 12 and Month 24 examinations, and two subjects 
were on medications at the Month 36 examination. Month 
36 IOP for these four subjects ranged from 13 mmHg to 
15.7 mmHg.
Best-corrected visual acuity, slit lamp, 
pachymetry
The proportion of eyes with BCVA of 20/40 or better was 
66.7% at the screening examination, 73.7% at 12 months 
postoperative, 71.8% at 24 months, and 76.7% at 36 months 
(Table 2). Three eyes experienced BCVA loss of $1 line 
from preoperative BCVA due to progression of preexisting 
cataract not related to stent implantation. All three subjects 
had bilateral cataracts. One of these subjects underwent 
cataract surgery and reported with 20/20 BCVA at their Month 
36 examination. The other two subjects had last reported 
BCVA of 20/50 and 20/40. No abnormal slit lamp findings 
were noted after the 1-week postoperative visit. C:D ratio was 
stable over time (Table 3) as was visual field (Table 4). Mean 
central corneal thickness was stable over time (535.0±32.7 µm 
at screening and 538.7±33.8 µm at 36 months).
adverse events and secondary surgical 
intervention
Ten adverse events were reported in eight eyes in the per 
protocol population (Table 5). As stated earlier, BCVA loss 
of $1 line due to progression of existing cataract was reported 
in three subjects, with subsequent cataract surgery performed 
in one subject. Two subjects died during the postoperative 
follow-up. One subject experienced hyphema that filled the 
anterior chamber at 2 weeks postoperative, requiring surgical 
irrigation of the anterior chamber. At the time of the event, IOP 
was 30 mmHg and BCVA was hand movement. The vision 
improved after clearing the hyphema, and IOP decreased 
after administration of topical ocular hypotensive medication. 
Medication was discontinued at Month 3, at which time IOP 
was 11 mmHg. The subject presented with initial cataract over 
the postoperative period that was deemed unrelated to the study 
treatment. At Month 36, this subject’s IOP was 13 mmHg on 
no medication with BCVA =20/25. Proliferative diabetic retin-
opathy was reported in one subject, and scar from age-related 
macular degeneration was reported in one subject.
Discussion
Because of the transient IOP reduction associated with pha-
coemulsification alone, the efficacy of iStent implantation is 
more difficult to gauge when combined with cataract surgery. 
This is the first MIGS study to evaluate long-term outcomes of 
implantation of two iStent devices as a stand-alone treatment 
for patients with OAG. The study involved multiple surgeons, 
thereby yielding some external validation of the safety of the 
surgical technique. The data presented in this publication 
span a 3-year postoperative period. The high level of subject 
accountability, including 100% accountability through 2 years 
and only five subjects lost to follow-up at 3 years, adds to the 
strength of the evidence from this small study.
Table 2 BCVa by visit, per protocol population
PRE M6 M12 M18 M24 M30 M36
n 39 37 38 39 39 30 30
20/40 or better 26 (66.7%) 26 (70.3%) 28 (73.7%) 28 (71.8%) 28 (71.8%) 23 (76.7%) 23 (76.7%)
20/100 or better 34 (87.2%) 32 (86.5%) 33 (86.8%) 34 (87.2%) 34 (87.2%) 26 (86.7%) 27 (90.0%)
20/200 or better 39 (100.0%) 37 (100.0%) 38 (100.0%) 39 (100.0%) 39 (100.0%) 30 (100.0%) 30 (100.0%)
Abbreviations: BCVa, best-corrected visual acuity; M, month; Pre, preoperative.
Table 3 C:D ratio by visit, per protocol population
PRE M12 M24 M36
n 39 39 39 30
#0.5 6 (15.4%) 6 (15.4%) 6 (15.4%) 5 (16.7%)
.0.5 and #0.8 22 (56.4%) 22 (56.4%) 22 (56.4%) 18 (60.0%)
.0.8 11 (28.2%) 11 (28.2%) 11 (28.2%) 7 (23.3%)
Note: C:D ratio = cup:disk ratio.
Abbreviations: M, month; Pre, preoperative.
Table 4 Visual field,a per protocol population
PRE M12 M24 M36
n 35 35 35 27
Mean deviation
Mean (dB) -4.95 -4.16 -4.00 -3.97
sD (dB) 2.52 2.66 3.14 2.31
Pattern standard deviation
Mean (dB) 3.05 2.82 2.96 2.37
sD (dB) 2.15 2.36 2.22 1.63
Notes: aFour subjects with eccentric VA did not have visual field measurements. One 
of these subjects did not have a Month 36 examination (died before examination).
Abbreviations: sD, standard deviation; M, month; Pre, preoperative; Va, visual 
acuity.
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Table 5 adverse events, per protocol population
Event N=39, n (%)
BCVa loss due to progression of preexisting cataract 3 (7.7)
Death 2 (5.1)
hyphema 1 (2.6)
initial cataract 1 (2.6)
Proliferative diabetic retinopathy 1 (2.6)
scar from age-related macular degeneration 1 (2.6)
secondary surgical intervention (cataract surgery) 1 (2.6)
Total adverse events 10 (25.6)
Total subjects with adverse events 8 (20.5)
Abbreviation: BCVa, best-corrected visual acuity.
This prospective pilot study showed that phakic and 
pseudophakic subjects with OAG can safely be implanted 
with two iStent devices. No device related adverse events 
were observed, and no subjects experienced hypotony. 
Adverse events mostly involved BCVA loss due to progres-
sion of preexisting cataract. In patients under such a health 
care system, surgery is reserved for advanced vision loss. 
With the exception of one procedure-related early postop-
erative hyphema that resolved at 1 week after irrigation and 
without further sequelae, no adverse events were considered 
related to iStent implantation.
Subjects experienced reduction in IOP through 3 years 
postoperative from their unmedicated baseline IOP that was 
both clinically significant (37%) and statistically significant 
(P,0.001). Of even greater significance is that subjects’ 
IOP was 26% lower (P,0.001) without medications 3 years 
after receiving iStents than with medications before surgery. 
Many glaucoma patients will require multiple medications 
for their disease. Although adding a second medication 
typically reduces IOP by an additional 2.5–3.9 mmHg,11,12 
the incidence of medication nonadherence has been shown 
to range from 30% to 80%.13,14 Because the mean IOP in our 
study was 5.5 mmHg lower 3 years after surgery compared 
to preoperative IOP on one medication, it is likely that these 
subjects’ IOP would have been higher had they been pre-
scribed multiple medications instead of receiving two stents. 
Most subjects experienced significant IOP reduction without 
the need for medication; only two subjects were taking ocu-
lar hypotensive medication at their Month 36 examination. 
A key advantage of ab interno glaucoma implants over medi-
cations is reduced dependence on patient compliance, and this 
might theoretically improve long-term outcomes. Thus, the 
well-known limitations of medical therapy administration, 
persistence, and adherence are avoided with an implantable 
glaucoma device that provides continuous therapy indepen-
dent of patient or physician involvement.
Numerous studies have shown IOP and medication 
reduction after implantation of a single stent in conjunction 
with cataract surgery in patients with mild-to-moderate dis-
ease on one to three medications. The work by Samuelson 
et al, Craven et al, and Fea demonstrated IOP reduction 
of #18 mmHg with reduced medication burden through 
1 year postoperative.1–3 In the US pivotal trial, mean IOP at 
1 year was 17.0±2.8 mmHg in the iStent group on an aver-
age number of 0.2±0.6 ocular hypotensive medications.1 
Although mean IOP in the stent group and control group at 
1 year was similar, the mean number of medications required 
to control IOP was significantly lower in the stent group 
(0.2±0.6 vs 0.4±0.7; P=0.011).2 Furthermore, Samuelson 
et al showed 66% of subjects implanted with one iStent in 
conjunction with cataract surgery achieved an IOP reduction 
of $20% 1 year after surgery without the need for ocular 
hypotensive medication.1 After 2 years postoperative, 61% 
of subjects from this study still reported IOP reduction 
of $20% from baseline.2 A separate study showed that 
eyes implanted with iStent during cataract surgery reported 
with a mean IOP decrease of 16.33% 3 years after surgery 
and 47% did not require ocular hypotensive medication.6 
In our study, 92.3% of subjects had IOP reduction .20%, 
without medication at 1 year, and 66.7% experienced 40% 
reduction.
Belovay et al showed that implantation of two or three 
iStent devices in conjunction with cataract surgery in patients 
with moderate-to-severe disease on two to three medications 
resulted in IOP reduction to a mean IOP of 14.3 mmHg 1 year 
postoperatively.8 These findings are in accord with initial 
work established by Bahler et al that showed significant 
increased outflow facility and reduced IOP after implantation 
of a single stent and further increase in outflow facility and 
reduced IOP when multiple stents were implanted.7
More recent work by Ahmed et al demonstrated safety 
and effectiveness through 18 months following treatment 
with two trabecular bypass stents and one presumptive post-
operative prostaglandin in patients with OAG not controlled 
on two preoperative medications.15 In their study, patients 
achieved IOP reduction of 20% with reduction of one medi-
cation from their preoperative status, with IOP #14 mmHg 
through 1.5 years. Our current work focused on eyes in a 
slightly earlier stage of disease. In our study, IOP in OAG 
eyes not controlled on one preoperative medication was 
managed to a mean of 15.2 mmHg at 3 years postoperatively 
without ocular hypotensive medication. While the various 
studies are not directly comparable, they do show that single 
and multiple iStent devices are capable of achieving, and 
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 sustaining through several years, target IOPs for various 
stages of disease. Multiple iStent devices may be a viable 
option for patients who need additional IOP reduction in 
order to delay the progression of glaucoma.
Several limitations of this study were identified. Because 
of the small number of pseudophakic subjects, outcomes were 
not stratified by preoperative lens status. A control group 
was not included, and the study design was open label. All 
subjects were Caucasian, and all subject evaluations were 
performed at a single site. Therefore, it is not possible to 
assess study site effects or measurement variability across 
study centers. Measurements of IOP at each examination 
were not recorded at multiple time points. The preoperative 
status of the crystalline lens was not graded. This population 
had not undergone previous incisional surgery, and most 
subjects were on a preoperative regimen of beta-blockers. 
The significant IOP reduction observed in this study may 
be greater than IOP reduction in eyes with more advanced 
glaucoma and/or in which the distal outflow system is less 
functional. However, the long-term data collected in a stable 
cohort over the 3-year period offer valuable insight about 
this treatment method. Continued IOP monitoring of this 
patient cohort is a part of an ongoing study. We also welcome 
larger, multicenter controlled studies to further corroborate 
our findings.
Our study confirmed that long-term IOP reduction to 
15 mmHg is possible after implantation of multiple iStent 
devices without cataract surgery, without postoperative 
medication burden, and without significant postoperative 
adverse effects. Management of chronic OAG with multiple 
medications is often associated with poor compliance and 
with local or systemic side effects. A safe and effective 
implant procedure that provides a clinically and statistically 
significant IOP reduction in mild-to-moderate OAG may be 
a preferable alternative for some patients.
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